IDB-003
IDB-003 is an orally active inhibitor of the human ribosomal peptidyl transferase center (PTC). IDB-003 exhibits antiproliferative activity against MYC-dependent cancer cells. IDB-003 binds to PTC, maintains ribosomal RNA interactions, blocks translation via context-dependent nascent polypeptide chain interactions, depletes MYC and CCND1, activates JNK phosphorylation through ribosomal collision, and downregulates the MYC target pathway. IDB-003 inhibits the growth of triple-negative breast cancer xenografts in mice. IDB-003 can be used for the research of triple-negative breast cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 3079716-11-0
- Formel: C22H22FN3O4
- Molecular Weight:411.43
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 22Rv1 | EC50 |
0.042 μM
|
Antiproliferative activity against human 22Rv1 prostate cancer cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Fluor assay.
Antiproliferative activity against human 22Rv1 prostate cancer cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Fluor assay.
|
41735331 |
| HCC1143 | EC50 |
0.132 μM
|
Antiproliferative activity against human HCC-1143 triple-negative breast cancer cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Fluor assay.
Antiproliferative activity against human HCC-1143 triple-negative breast cancer cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Fluor assay.
|
41735331 |
| LS-411N | EC50 |
0.021 μM
|
Antiproliferative activity against human LS411N colorectal cancer cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Fluor assay.
Antiproliferative activity against human LS411N colorectal cancer cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Fluor assay.
|
41735331 |
| MCF7 | EC50 |
0.096 μM
|
Antiproliferative activity against human MCF7 HR+/HER2- breast cancer cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Fluor assay.
Antiproliferative activity against human MCF7 HR+/HER2- breast cancer cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Fluor assay.
|
41735331 |
| MRC5 | EC50 |
0.331 μM
|
Antiproliferative activity against human MRC5 fibroblast cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Fluor assay.
Antiproliferative activity against human MRC5 fibroblast cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Fluor assay.
|
41735331 |
In Vitro
IDB-003 (72 h) potently inhibits the proliferation of 22Rv1, HCC-1143, LS411N and MCF7 cancer cells (EC50 values 0.021-0.132 μM), while exhibits weak activity against MRC5 fibroblasts (EC50 0.331 μM)[1].
IDB-003 (1-10 μM; 2 h-<4 h) depletes the short-lived oncoproteins MYC and CCND1 in MCF7 cells: this depletion is achieved within 2-4 h at treatment concentrations of 1 μM and 10 μM, respectively, without altering the levels of the long-lived proteins CDK4 and tubulin[1].
IDB-003 (2-72 h) depletes MYC protein in HCC-1143 cells in a concentration-dependent manner within 2 h, which correlates with reduced cell viability after 72 h of treatment[1].
IDB-003 (1.27 μM; 60 min) induces context-dependent translation arrest in HCC-1143 cells, preferentially targeting nascent polypeptide chains with an aliphatic residue at position −1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF7 breast cancer cells
-
Concentration:1 μM (15 min-8 h incubations); 10 μM (<4 h incubation)
-
Incubation Time:15 min, 30 min, 1 h, 2 h, 4 h, 8 h (1 μM); <4 h (10 μM)
-
Result:Depleted CCND1 rapidly (evident by 1-2 h) and reduced MYC levels (observable after 2 h) at 1 μM.
Depleted MYC rapidly within <4 hours at 10 μM.
Left abundance of longer-lived proteins CDK4 and tubulin stable over the same time course.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice (female, 6-8 weeks old)[1]
-
Dosage:3 mg/kg; 10 mg/kg
-
Administration:p.o.; twice daily; 28 days (3 mg/kg); p.o.; twice daily; 11 days, followed by 2-day holiday, then resuming twice daily for remainder of 28 days (10 mg/kg)
-
Result:Achieved 58% tumor growth inhibition (TGI) compared to vehicle control.
Achieved 80% tumor growth inhibition (TGI) compared to vehicle control.
Downregulated MYC targets v1 pathway as the most significantly altered pathway in endpoint tumor samples.
Chemical Information
-
CAS. Nr. 3079716-11-0
-
Molecular Weight 411.43
-
Formel C22H22FN3O4
-
SMILES
FC1=CC=CC(CNC(O[C@H]([C@H](CN2)O)[C@H]2CC3=CC=C(C4=CN=CO4)C=C3)=O)=C1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)